SUMMARY
The research of Scott M. Ebert, Ph.D., focuses on the molecular mechanisms of skeletal muscle atrophy. This is a highly prevalent condition caused by aging, muscle disuse, malnutrition, critical illness and a wide range of chronic illnesses.
Muscle atrophy has a broad clinical impact. Despite its prevalence and severity, skeletal muscle atrophy lacks a specific and effective pharmacological therapy. The therapy for skeletal muscle atrophy represents an enormous unmet medical need. Dr. Ebert's research addresses two general areas. He explores the discovery and characterization of novel molecular mechanisms of skeletal muscle atrophy. He also researches the discovery and development of new potential therapeutic approaches for skeletal muscle atrophy.
Focus areas
- Discovery and characterization of novel molecular mechanisms of skeletal muscle atrophy. Dr. Ebert uses novel molecular biology and biochemical techniques along with mouse models to discover and characterize several previously unrecognized molecular mediators of skeletal muscle atrophy, including ATF4, Gadd45a, p21 and MEKK4.
- Discovery and development of new potential therapeutic approaches for skeletal muscle atrophy. Dr. Ebert performs mechanistic studies on skeletal muscle atrophy and has a novel systems-based strategy that relies on mRNA expression signatures of the condition. These areas pertain to both human and mouse muscle. Dr. Ebert is working to discover small molecules that reduce skeletal muscle atrophy. The ultimate goal is to translate these findings into products that improve human health.
Significance to patient care
Effects of muscle atrophy are significant and numerous. They include weakness, impaired activity and metabolism, falls, prolonged hospitalization, loss of independent living, decreased quality of life, and increased mortality. By finding the mechanisms that lead to muscle atrophy, Dr. Ebert hopes to help generate new medicines and nutritional approaches to preserve muscle mass and strength.